Patrick H Luckett, Michael Olufawo, Bidhan Lamichhane, Ki Yun Park, Donna Dierker, Gabriel Trevino Verastegui, Peter Yang, Albert H Kim, Milan G Chheda, Abraham Z Snyder, Joshua S Shimony, Eric C Leuthardt
PURPOSE: Glioblastoma (GBM) is the most common and aggressive malignant glioma, with an overall median survival of less than two years. The ability to predict survival before treatment in GBM patients would lead to improved disease management, clinical trial enrollment, and patient care. METHODS: GBM patients (N = 133, mean age 60.8 years, median survival 14.1 months, 57.9% male) were retrospectively recruited from the neurosurgery brain tumor service at Washington University Medical Center...
September 5, 2023: Journal of Neuro-oncology